Evidence map›Paper›PMID 37275960›Full record

ReviewFrontiers in molecular biosciences2023

Targeting heparan sulfate-protein interactions with oligosaccharides and monoclonal antibodies.

Miaomiao Li, Lars C Pedersen, Ding Xu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Miaomiao LiDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, the State University of New York, Buffalo, NY, United States.
Lars C PedersenGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, United States.
Ding XuDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, the State University of New York, Buffalo, NY, United States.
University at Buffalo, State University of New York · USNational Institute of Environmental Health Sciences · US

Funding

In vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2M
The role of heparan sulfate in cathepsin K biologyR01DE031273 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JIAN LIU, Ding Xu · 2022 to 2026
$2.7M
Heparan Sulfate–Osteoprotegerin Interactions in Bone RemodelingR01AR070179 · NIAMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI XU, DING · 2017 to 2021
$1.7M
Demystify Heparan Sulfate–Sclerostin Interactions in Bone FormationR03DE031838 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LI, MIAOMIAO · 2023 to 2024
$319k
NHLBI NIH HHS R01 HL094463NIAMS NIH HHS R01 AR070179NIDCR NIH HHS R01 DE031273NIDCR NIH HHS R03 DE031838
6 · The paper itself

Abstract

Heparan sulfate-binding proteins (HSBPs) are structurally diverse extracellular and membrane attached proteins that interact with HS under normal physiological conditions. Interactions with HS offer an additional level of control over the localization and function of HSBPs, which enables them to behave in a more refined manner. Because all cell signaling events start at the cell membrane, and cell-cell communication relies on translocation of soluble factors across the extracellular matrix, HS occupies an apical position in cellular signal transduction by interacting with hundreds of growth factors, cytokines, chemokines, enzymes, enzyme inhibitors, receptors and adhesion molecules. These extracellular and membrane proteins can play important roles in physiological and pathological conditions. For most HS-binding proteins, the interaction with HS represents an essential element in regulating their normal physiological functions. Such dependence on HS suggests that manipulating HS-protein interactions could be explored as a therapeutic strategy to selectively antagonize/activate HS-binding proteins. In this review, we will discuss current understanding of the diverse nature of HS-HSBP interactions, and the latest advancements in targeting the HS-binding site of HSBPs using structurally-defined HS oligosaccharides and monoclonal antibodies.

Indexed as

crystallizationdrug targetheparan sulfate binding proteinsmonoclonal antibodyoligosaccharidespecificity

Identifiers

PMID37275960
PMCPMC10235622
OpenAlexW4377097851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.